Cisplatin(IV)-fatty acid prodrug-bound albumin nanoparticles: In vitro, in silico, and in vivo evaluation in breast cancer therapy
{{output}}
The therapeutic outcome of cisplatin (CP) in triple-negative breast cancer (TNBC) is hindered by irreversible protein binding, systemic toxicities, and resistance development. Therefore, we synthesized three CP(IV) prodrugs of fatty acids (FAs) possessing reve... ...
